Krystexxa?

Krystexxa is a medication used to treat chronic refractory gout [1]. It is administered intravenously [2].

How does Krystexxa work?

Krystexxa contains the enzyme pegloticase, which breaks down uric acid in the body [3]. This process helps to reduce the levels of uric acid, thereby preventing gout flares and tophi formation [4].

What is gout and why is it considered refractory?

Gout is a form of inflammatory arthritis caused by the buildup of uric acid crystals in the joints [5]. Chronic refractory gout refers to cases where other treatments have been unsuccessful in managing uric acid levels or symptoms [4].

When does Krystexxa patent exclusivity expire?

Information on the specific patent expiry dates for Krystexxa may vary and is often subject to ongoing legal challenges and regulatory exclusivities. For detailed and up-to-date patent information, DrugPatentWatch.com is a valuable resource [6].

Who makes Krystexxa?

Krystexxa is manufactured by Horizon Therapeutics [7].

What are the risks or side effects associated with Krystexxa?

The most serious potential side effect of Krystexxa is anaphylaxis, a severe allergic reaction that can occur during or after administration [2]. Patients are monitored for signs of allergic reactions during and after treatment [4]. Other side effects can include gout flares, nausea, bruising, and injection site reactions [4].

What alternatives are available for chronic refractory gout?

Other treatments for gout include oral medications like allopurinol and febuxostat, which reduce uric acid production, and probenecid, which increases uric acid excretion [5]. For patients who cannot tolerate or do not respond to these options, Krystexxa offers an alternative intravenous treatment [4].

How effective is Krystexxa?

Clinical trials have shown that Krystexxa can significantly lower serum uric acid levels in patients with chronic refractory gout [4]. This reduction in uric acid is associated with a decrease in gout flares and improvement in tophi [3][4].

What are patient considerations for Krystexxa treatment?

Patients considering Krystexxa should discuss their medical history, especially any history of allergic reactions or heart failure, with their doctor [4]. The intravenous administration requires regular clinic visits [2]. Due to the risk of anaphylaxis, patients are typically premedicated to reduce this risk [4].

Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050891s036,057517s006lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724507/
[4] https://www.hcp.horizontherapeutics.com/our-medicines/krystexxa
[5] https://www.cdc.gov/arthritis/basics/gout.html
[6] https://drugpatentwatch.com/
[7] https://www.horizontherapeutics.com/